Impact of Grade, Hormone Receptor, and HER-2 Status in Women with Breast Cancer on Response to Specific Chemotherapeutic Agents by in vitro Adenosine Triphosphate-based Chemotherapy Response Assay.
10.3346/jkms.2009.24.6.1150
- Author:
Ja Seung KOO
1
;
Woohee JUNG
;
Eunah SHIN
;
Hy de LEE
;
Joon JEONG
;
Kun Hong KIM
;
Hyeongjae JEONG
;
Soon Won HONG
Author Information
1. Department of Pathology, Yonsei University College of Medicine, Seoul, Korea. soonwonh@yuhs.ac
- Publication Type:Original Article ; Research Support, Non-U.S. Gov't
- Keywords:
Breast Neoplasms;
Drug Therapy;
Tumor Markers
- MeSH:
Adenosine Triphosphate/*metabolism;
Adult;
Aged;
Antineoplastic Agents/*therapeutic use;
*Breast Neoplasms/classification/drug therapy/pathology;
Doxorubicin/therapeutic use;
Drug Screening Assays, Antitumor/*methods;
Epirubicin/therapeutic use;
Female;
Fluorouracil/therapeutic use;
Humans;
Middle Aged;
Paclitaxel/therapeutic use;
Receptor, erbB-2/genetics/*metabolism;
Receptors, Estrogen/genetics/metabolism;
Receptors, Progesterone/genetics/metabolism
- From:Journal of Korean Medical Science
2009;24(6):1150-1157
- CountryRepublic of Korea
- Language:English
-
Abstract:
This study was designed to assess whether histological and biological factors of breast cancer can predict chemoresponse to specific agents. Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) was employed to retrieve chemoresponse to 5-fluorouracil (5-FU), doxetaxel, doxorubicin, epirubicin, and paclitaxel in 49 patients. Tumors with high histologic and nuclear grade have higher response rate to doxorubicin (P<0.05) and palitaxel (P<0.05). Estrogen receptor (ER)-negative tumors respond well to doxorubicin (P=0.038), and progesterone receptor (PR)-negative tumors to 5-FU (P=0.039), doxetaxel (P=0.038), doxorubicin (P=0.000), epirubicin (P=0.010), and paclitaxel (P=0.003). Among the breast cancer subtypes determined by ER, PR, and HER-2 immunohistochemical stains, the HER-2+/ER- subtype has a higher response rate to doxorubicin (P=0.008). This in vitro result suggests that the combination of histologic and nuclear grade, hormone receptor, and HER-2 status can be a predictive factor of response to specific chemotherapy agents. Further in vivo study should be followed for clinical trials.
